Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395580 | 0.87 | TSHR (0.31) | TSHRTDP1 | |
| SCHEMBL12778810 | 0.85 | FDPS (0.30) | — | |
| SCHEMBL13818441 | 0.82 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL12778794 | 0.77 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL16154677 | 0.74 | — | — | |
| SCHEMBL8053513 | 0.73 | — | — | |
| SCHEMBL12778836 | 0.72 | — | — | |
| SCHEMBL12778820 | 0.69 | — | — | |
| SCHEMBL4119428 | 0.69 | — | — | |
| SCHEMBL6136603 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951043-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-09 | — | — | US | disclosed |
| US-7897789-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-7750184-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750184-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100076065-A1 | VITAMIN D RECEPTOR MODULATORS | LU JIANLIANG | 2010-03-25 | — | — | US | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7595345-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7582775-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7468449-B2 | Phenyl-furan compounds as vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
| US-20070149810-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070105951-A1 | Phenyl-furan compounds as vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | TSHR 4738/4885TDP1 1814/4885 |
| US-20100076065-A1 | VITAMIN D RECEPTOR MODULATORS | VDR, CYP2R1, CYP24A1 | TSHR 387/4885TDP1 4642/4885 |
| US-20080200552-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | TSHR 480/4885TDP1 4786/4885 |
| US-20070106095-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | TSHR 602/4885TDP1 4642/4885 |
| US-20070149810-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | TSHR 387/4885TDP1 4642/4885 |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | TSHR 4662/4885TDP1 1782/4885 |
| US-20070105951-A1 | Phenyl-furan compounds as vitamin d receptor modulators | VDR, CYP24A1, CYP2R1 | TSHR 1025/4885TDP1 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.